KOSDAQBiotech & Pharma293780

Aptabio Therapeutics

₩4,280▼ 0.47%2026-11-18 close
Market Cap
₩120.2B
Turnover
₩96,067,760
Volume
20K
Shares out.
28.1M
PER
—
PBR
3.3×
EPS
-₩573
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Clinical Progress and Persistent Losses, with Licensing as the Swing Factor

Revenue has grown mainly on pet products, but operating losses continued through 2025, and the direction of corporate value depends heavily on clinical results and licensing deals for the lead pipeline.

  1. 1

    Revenue rose from KRW 48.35 million in 2022 to KRW 3.7 billion in 2025, and pet products accounted for 91.8% of the KRW 3.6 billion cumulative revenue for the first three quarters of 2026.

  2. 2

    Operating loss was KRW 15.8 billion in 2025, a loss in each of the four years from 2022, and operating cash flow was -KRW 15.3 billion, a larger outflow than in 2024.

  3. 3

    The operating loss in the third quarter of 2026 was KRW 4.19 billion, the fifth straight quarterly loss in the last five quarters, while the second quarter of 2026 showed a KRW 1.12 billion net profit attributable to controlling shareholders despite an operating loss.

  4. 4

    Topline results from the global Phase 2 trial of APX-115 in contrast-induced acute kidney injury are guided for the second half of 2026, and these results are central to ongoing licensing talks.

  5. 5

    Because the last four quarters show a combined net loss attributable to controlling shareholders, the price-to-earnings ratio cannot be calculated, and the price-to-book ratio sits in a range with a large premium over net asset value.

02

Business structure

Aptabio Therapeutics develops drug candidates for cancer and diabetic complications based on its NOX inhibitor platform, but its revenue is currently dominated by pet products.

Pet products accounted for KRW 3.3 billion, or 91.8%, of the KRW 3.6 billion cumulative consolidated revenue for the first three quarters of 2026, and health functional food ODM sales were KRW 300 million.

The company entered the health functional food ODM business and pet care business in 2023, and in June 2025 it absorbed a pet products company whose prior-year revenue was KRW 2.4 billion, according to the company.

On October 1, 2026, the company acquired an additional 75% stake in the health functional food company GM Pharm, raising its ownership to 100%, and its results are scheduled to be consolidated from the fourth quarter.

According to the company, the deal adds a direct-to-consumer brand and is expected to diversify the revenue structure. On the drug side, APX-115 for contrast-induced acute kidney injury has completed dosing in a global Phase 2 trial, and a Phase 2b trial in diabetic kidney disease is ongoing in Korea.

APX-343A, an immuno-oncology candidate, has entered a combination trial with Merck (MSD) Keytruda, followed by the oral age-related macular degeneration candidate ABF-101 and the blood cancer candidate Apta-16.

Licensing revenue remains a small share of reported revenue, so pet products and health functional foods are currently driving the top line. No approved drug uses the NOX inhibitor mechanism yet, so the clinical data must prove the value of the pipeline.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.2B-₩3.4B−283.3%
2025Q4₩1B-₩5.7B−569.3%
2026Q1₩1B-₩6.1B−636.6%
2026Q2₩1.6B-₩3.6B−223.0%
2026Q3₩1.1B-₩4.2B−391.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩48,352,850-₩9.5B-₩10.6B−19661.2%−20.2%7.1%
2023₩300M-₩16.4B-₩12.1B−5055.6%−19.7%50.8%
2024₩3.4B-₩18.9B-₩29.4B−561.0%−54.2%42.9%
2025₩3.7B-₩15.8B-₩16.3B−428.4%−34.6%27.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Reported revenue rose from KRW 48.35 million in 2022 to KRW 324 million in 2023, KRW 3.36 billion in 2024, and KRW 3.7 billion in 2025. Revenue increased for three consecutive years from 2023 through 2025, and 2025 was the largest year in the 2022 to 2025 period.

Revenue in 2024 rose 937.8% year on year, which the company attributed to expansion of its health functional food and pet businesses. Revenue in 2025 rose 10.0% year on year, and the company cited higher revenue from a merger completed during the year as the main driver.

Operating loss was KRW 9.51 billion in 2022, KRW 16.4 billion in 2023, KRW 18.9 billion in 2024, and KRW 15.8 billion in 2025, a loss in each of the four years from 2022, with the loss narrowing in 2025. The operating margin improved from -19,661.2% in 2022 to -428.4% in 2025, but costs still far exceed revenue.

Press reports on 2024 indicated that KRW 14.6 billion of the KRW 19.1 billion in selling and administrative expenses was R&D, so much of the loss stems from clinical investment.

Net loss attributable to controlling shareholders was KRW 10.6 billion in 2022, KRW 12.1 billion in 2023, KRW 29.4 billion in 2024, and KRW 16.3 billion in 2025, and the net loss including non-controlling interests was disclosed at the same amounts.

On a quarterly basis, revenue in the second quarter of 2026 was KRW 1.6 billion, up 67.4% from the prior quarter, before falling 33.1% to KRW 1.07 billion in the third quarter, so quarterly revenue is volatile.

The KRW 1.12 billion net profit attributable to controlling shareholders in the second quarter of 2026 came alongside an operating loss of KRW 3.57 billion, which suggests non-operating items had a large effect. The debt ratio fell from 7.1% in 2022 to 27.2% in 2025.

Operating cash flow was -KRW 6.83 billion in 2022, -KRW 14.1 billion in 2023, -KRW 12.2 billion in 2024, and -KRW 15.3 billion in 2025.

05

Industry analysis

Aptabio's position is better described by its pipeline stage than by its revenue scale. A Korean equity research analyst argued that because the company continues to run losses from R&D spending, the key variable for corporate value is the outcome of major licensing deals rather than improvement in earnings.

The company points to several areas of unmet demand. In diabetic kidney disease, it says few fundamental treatment options exist, so development demand is high.

For contrast-induced acute kidney injury, the company says only supportive care such as fluid supply or antioxidants is available, which makes preventive drugs necessary. In immuno-oncology, competition over next-generation mechanisms is intensifying ahead of patent expiries for blockbuster drugs such as Keytruda.

In blood cancer, venetoclax has annual sales of about USD 2.6 billion, but resistance driven by high MCL-1 expression remains a challenge. In age-related macular degeneration, the company says deal activity for oral treatments is accelerating in global markets.

The main risk flagged is that although the NOX inhibitor mechanism has been demonstrated, no approved drug uses it yet.

Because the current revenue base is centered on pet products and health functional foods, the business model differs from peers in the same biopharma sector that explain earnings through licensing income.

06

Outlook

The timelines the company has disclosed differ by pipeline asset. The global Phase 2 trial of APX-115 in contrast-induced acute kidney injury completed dosing in April 2026, and the company said topline results are expected in the second half of 2026.

The company stated that if the candidate is successfully developed, it could become the first and first-in-class treatment in that area. Interim data from the Phase 2b trial in diabetic kidney disease in Korea are reported to be due in the second half of 2026.

On November 2, 2026, the company announced it would attend BIO-Europe 2026 and said a package deal combining the two kidney disease programs is included in discussions. APX-343A, an immuno-oncology candidate, first disclosed Phase 1 human data at ASCO 2026, and a combination trial with Merck Keytruda has since started.

The oral age-related macular degeneration candidate ABF-101 received notice from the FDA in June 2026 that its clinical hold was lifted, and the U.S. Phase 1 trial is resuming.

According to the company, the hold stemmed from administrative and procedural issues at a Japanese contract GLP testing facility, and dosing of patients is expected in the first half of 2027.

The blood cancer candidate Apta-16 has FDA orphan drug designation, was accepted as a poster at ESMO 2026, and the company plans to begin a Phase 1 trial in Korea in the second half of 2026.

The next periodic report, the 2026 annual report, will confirm full-year results and whether GM Pharm is reflected in consolidation.

07

Valuation

PER
—
PBR
3.3×
ROE
-38.3%
EPS
-₩573
BPS
₩1,355
Dividend per share
₩0

Aptabio's price-to-book ratio sits in a range with a large premium over net asset value, relative to the company's own history of profitability, which has been absent. Total equity at the end of 2025 was KRW 47.2 billion, all attributable to controlling shareholders, and total liabilities were KRW 12.8 billion.

On a net asset basis the balance sheet carries some capacity, but there is no earnings-based reference point. Because the combined net loss attributable to controlling shareholders over the last four quarters is KRW 15.8 billion, the price-to-earnings ratio cannot be calculated.

The company does not pay dividends, so its dividend yield is below the sector average. The company recorded no annual profit in any year from 2022 to 2025, which makes a historical price-to-earnings band difficult to use as a comparison.

The current share price is therefore hard to explain from reported earnings, and the key question is how much the market already reflects expectations for clinical results and licensing terms. With operating cash outflows continuing, funding conditions also weigh on how the valuation should be read.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Several pipeline programs advancing at once

APX-115 has completed dosing in a global Phase 2 trial and is awaiting topline results. APX-343A has entered a combination trial with Merck Keytruda, and ABF-101 resumed its U.S. Phase 1 trial after the FDA lifted the clinical hold. Apta-16 holds orphan drug designation, so several programs are moving through stages at the same time.

Expanding revenue base

Revenue grew from KRW 48.35 million in 2022 to KRW 3.7 billion in 2025, and cumulative revenue for the first three quarters of 2026 reached KRW 3.6 billion.

The company said concerns over the revenue requirement for listing had been resolved, and in October 2026 it secured 100% of GM Pharm, adding a direct sales channel for health functional foods.

Expanding licensing discussions

The company said it held talks with global pharmaceutical companies at BIO USA 2026 and BIO-Europe 2026. A package deal combining the two kidney disease programs is part of the discussions. The company said interest from new partners was higher than expected.

09

Bear factors

Loss structure and cash outflow

Operating loss in 2025 was KRW 15.8 billion, and operating cash flow was -KRW 15.3 billion. Press reports based on regulatory filings indicated that operating cash flow in the first quarter of 2026 was -KRW 8.0 billion, a larger outflow than the -KRW 6.5 billion a year earlier.

At the end of the first quarter of 2026, cash and cash equivalents were reported at KRW 7.8 billion, and convertible bonds with KRW 7.2 billion in remaining face value remain a liquidity variable.

Pet concentration and volatile quarterly results

Pet products generated 91.8% of cumulative revenue for the first three quarters of 2026. Third-quarter 2026 revenue was KRW 1.07 billion, down 10.1% from a year earlier, and the operating loss widened to KRW 4.19 billion.

The second-quarter 2026 net profit attributable to controlling shareholders occurred alongside an operating loss, so it may reflect a one-off or non-operating factor rather than a durable turn to profit.

Uncertainty in clinical results and licensing

Topline results for APX-115 are guided for the second half of 2026 and have not yet been reported. No approved drug uses the NOX inhibitor mechanism, so clinical data will determine much of the value. Because ABF-101 previously faced a clinical hold, further delays in its development timeline cannot be ruled out.

10

Risk factors

Funding and dilution risk

Operating cash outflows have continued since 2022, so the need for additional funding remains. Cash and cash equivalents were around KRW 7.8 billion at the end of the first quarter of 2026, and convertible bonds with KRW 7.2 billion in remaining face value could increase the share count if converted. The timing of licensing agreements will have a large effect on cash flows.

Clinical and regulatory risk

ABF-101 was subject to a clinical hold due to administrative issues at a Japanese non-clinical contract testing facility. No drug using the NOX inhibitor mechanism has been approved, so the uncertainty in clinical data is high. If major topline results fall short of expectations, the terms of licensing talks could weaken.

Business structure risk

Most revenue depends on pet products, so swings in consumer demand flow directly into results. The consolidation of GM Pharm and the 2025 merger effect change the revenue base, which may complicate year-on-year comparisons. With quarterly revenue moving around KRW 1 billion, the stability of annual results is limited.

11

What to watch next

  1. By end of 2026 (company's second-half topline plan)

    Topline results from the global Phase 2 trial of APX-115 in contrast-induced acute kidney injury. The results are central to licensing talks.

  2. Second half of 2026 (timing not fixed)

    Interim data from the Phase 2b trial in diabetic kidney disease in Korea, which may be linked to package deal talks.

  3. Within 2026 (company plan)

    Whether the Phase 1 trial of Apta-16 starts in Korea, an indicator of when the orphan-designated candidate enters clinical testing.

  4. First half of 2027 (company plan)

    Whether patient dosing with ABF-101 begins, which shows the actual pace of the U.S. Phase 1 trial after the clinical hold was lifted.

  5. End of March 2027 (annual report filing deadline)

    In the 2026 annual report, full-year operating loss, operating cash flow, whether GM Pharm is consolidated, and the outstanding convertible bond balance. This is the next periodic report and the first disclosure of fourth-quarter results.

12

Overall view

Aptabio has broadened its revenue base through pet products and health functional foods, reaching KRW 3.7 billion in 2025, but operating losses still totaled KRW 15.8 billion in 2025, extending a four-year run of annual losses.

Quarterly revenue in 2026 has moved around KRW 1 billion, and the second-quarter 2026 turn to a net profit attributable to controlling shareholders appears to have been driven largely by non-operating items.

On cash, operating cash outflow in the first quarter of 2026 was larger than a year earlier, and convertible bonds with KRW 7.2 billion in remaining face value remain a liquidity variable.

The factors that will shape corporate value are pipeline results such as the global Phase 2 topline for APX-115, the combination trial with an immuno-oncology drug, and the resumed macular degeneration trial, along with licensing terms.

Bullish factors include several clinical programs advancing at once and a larger revenue base since 2022. Bearish factors include continuing losses and cash outflows, concentration of revenue in pet products, and the need for clinical validation of a NOX inhibitor mechanism that has no approved drug yet.

The next checkpoints are the second-half 2026 clinical data and the 2026 annual report. This report does not present an investment opinion or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. sisajournal-e.com
  3. medicopharma.co.kr
  4. m.yakup.com
  5. press9.kr
  6. mt.co.kr
  7. sisajournal-e.com
  8. m.news.nate.com
  9. hankyung.com
  10. medipana.com
  11. news.nate.com
  12. pharmnews.com
  13. wowtv.co.kr
  14. m.news.nate.com
  15. v.daum.net
  16. medipana.com
  17. joongangenews.com
  18. supple.kr

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis